Lundbeck to Present Innovative Neurology Data at AAN 2026 Meeting At the American Academy of Neurology Annual Meeting 2026, Lundbeck will showcase pivotal data on migraine and epilepsy from its neurology portfolio, emphasizing its commitment to addressing unmet medical needs.

Lundbeck to Present Innovative Neurology Data at AAN 2026 Meeting #USA #Chicago #Lundbeck #bexicaserin #Vyepti

Lundbeck's Bexicaserin Shows Long-Term Efficacy for Childhood Epilepsies at AES 2025 Lundbeck revealed promising long-term data for bexicaserin, an investigational treatment for childhood-onset epilepsies, showing significant seizure reduction and safety.

Lundbeck's Bexicaserin Shows Long-Term Efficacy for Childhood Epilepsies at AES 2025 #Denmark #Lundbeck #bexicaserin #Valby #DEEs

Lundbeck Unveils Encouraging Phase 2 Data for Bexicaserin in Rare Childhood Epilepsies at AES 2025 Lundbeck reveals new long-term outcomes for bexicaserin, showing sustained reduction in seizure frequency in rare childhood-onset epilepsies during AES 2025.

Lundbeck Unveils Encouraging Phase 2 Data for Bexicaserin in Rare Childhood Epilepsies at AES 2025 #Denmark #Epilepsy #Lundbeck #bexicaserin #Valby

Lundbeck Unveils Promising New Data on Bexicaserin at American Epilepsy Society Meeting Lundbeck's latest findings on bexicaserin show hope for treating rare childhood-onset epilepsies, highlighting early seizure reductions and long-term efficacy.

Lundbeck Unveils Promising New Data on Bexicaserin at American Epilepsy Society Meeting #Denmark #Epilepsy #Lundbeck #bexicaserin #Valby

Lundbeck Unveils New Bexicaserin Data for Childhood Epilepsies at AES 2025 At the AES 2025 Annual Meeting, Lundbeck introduces promising data on Bexicaserin for treating seizures in childhood epilepsy, showing early and sustained effects.

Lundbeck Unveils New Bexicaserin Data for Childhood Epilepsies at AES 2025 #USA #Atlanta #Lundbeck #bexicaserin #DEEs

Bexicaserin, a highly selective 5HT2C receptor superagonist, is an investigational molecule in clinical development that has progressed to phase 3 for the treatment of seizures associated with DEEs.
doi.org/10.1111/epi....
#epilepsy #ILAE #Epilepsia #bexicaserin #DEE #seizures #serotonin

Lundbeck's Bexicaserin Gains Breakthrough Therapy Status in China for Severe Epilepsies Lundbeck's investigational drug Bexicaserin has been granted Breakthrough Therapy Designation in China for treating severe rare epilepsies, highlighting urgent patient needs.

Lundbeck's Bexicaserin Gains Breakthrough Therapy Status in China for Severe Epilepsies #China #Lundbeck #bexicaserin #Valby #Developmental_Epileptic_Encephalopathies

Lundbeck Reveals Promising Results on Bexicaserin at Upcoming Epilepsy Congress Lundbeck will unveil groundbreaking data on Bexicaserin's long-term effects on seizure frequency in rare epilepsy at the International Congress.

Lundbeck Reveals Promising Results on Bexicaserin at Upcoming Epilepsy Congress #Denmark #Epilepsy #Lundbeck #bexicaserin #Valby

Lundbeck to Unveil Groundbreaking Bexicaserin Data at International Epilepsy Congress Lundbeck will present new findings on bexicaserin's effects on seizure frequency in patients with rare epilepsy at the upcoming congress. This marks a pivotal moment in epilepsy treatment.

Lundbeck to Unveil Groundbreaking Bexicaserin Data at International Epilepsy Congress #Denmark #Epilepsy #Lundbeck #bexicaserin #Valby

Lundbeck Highlights Promising Bexicaserin Data at AAN 2025 Annual Meeting H. Lundbeck A/S is set to present encouraging interim results from its research on bexicaserin at the upcoming AAN Annual Meeting, showcasing positive advancements in treating epilepsy disorders.

Lundbeck Highlights Promising Bexicaserin Data at AAN 2025 Annual Meeting #USA #San_Diego #Lundbeck #bexicaserin #AAN2025

Lundbeck's Exciting Pipeline Findings Set to Shine at American Academy of Neurology Conference Lundbeck will showcase positive interim results from its PACIFIC trial at the AAN Annual Meeting, demonstrating its commitment to treating complex neurological conditions.

Lundbeck's Exciting Pipeline Findings Set to Shine at American Academy of Neurology Conference #USA #San_Diego #Lundbeck #bexicaserin #PACIFIC_Trial

Lundbeck's Promising Results for Bexicaserin in Patients with Severe Epileptic Disorders H. Lundbeck A/S has reported promising outcomes from the open-label extension of the PACIFIC trial, showcasing bexicaserin's significant efficacy and safety profile in patients with developmental and epileptic encephalopathies.

Lundbeck's Promising Results for Bexicaserin in Patients with Severe Epileptic Disorders #Denmark #Lundbeck #bexicaserin #PACIFIC_Trial #Valby

Lundbeck Showcases Commitment to Epilepsy Care at AES Annual Meeting At the annual AES meeting in Los Angeles, Lundbeck presents vital data on bexicaserin, highlighting its potential for epilepsy treatment and its dedication to the community.

Lundbeck Showcases Commitment to Epilepsy Care at AES Annual Meeting #United_States #Los_Angeles #Epilepsy #Lundbeck #bexicaserin